Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Materials Select Sector SPDR Fund — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B), while Materials Select Sector SPDR Fund trades at $50 (market cap $7.85B). The key difference: Kymera Therapeutics Inc. Common Stock and Materials Select Sector SPDR Fund are close in size by market cap, and Kymera Therapeutics Inc. Common Stock is more actively traded (779,107 versus 7,897,808). Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Materials Select Sector SPDR Fund for 71 Days on average.
| KYMR | XLB | |
|---|---|---|
Market Cap | $8.87B | $7.85B |
Volume | 779,107 | 7,897,808 |
Sector | Health | — |
52-Week High | $127.31 | $53.67 |
52-Week Low | $55.80 | $42.23 |
Typical Hold Time | 0 Days | 71 Days |
Enterprise Value | $8.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XLB trades at $49.72 with a modest 0.57% daily gain, though technical indicators signal bearish momentum with moving averages and ADX pointing lower. The materials ETF faces headwinds from sector concentration risks, with chemicals comprising 49% of assets. Recent analysis suggests much of the cyclical recovery appears priced in, limiting near-term upside potential despite infrastructure and manufacturing tailwinds.
Outlook remains cautious as technical weakness combines with valuation concerns. The ETF offers efficient exposure to materials but faces competition from AI-focused sectors. Key risks include sector concentration and cyclical sensitivity, while potential catalysts include infrastructure spending and supply chain diversification efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
